Skip to main content

Table 3 IL-10 Gene Promoter Polymorphisms With Initial Response to IFN-α therapy in patients with HBV

From: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

  SR(%) NR(%) OR p
Allele n = 24 × 2 = 48 n = 28 × 2 = 56   
-819C 4(8.3) 16(28.6) 0.23 0.01
-819T 44(91.6) 40(71.4) 4.4 0.01
-592C 8(16.6) 32(57.1) 0.15 <0.01
-592A 40(83.3) 24(42.9) 6.67 <0.01
-1082A 47(97.9) 53(94.6) 2.66 0.62
-1082G 1(2.1) 3(5.4) 0.38 0.62
Genotype n = 24 n = 28   
-592A/A 19(79.1) 4(14.3) 22.8 <0.01
-592A/C 2(8.3) 18(64.3) 0.05 <0.01
-592C/C 3(12.5) 6(21.4) 0.52 0.48
-819T/T 21(87.5) 15(53.6) 6.07 0.02
-819T/C 2(8.3) 10(35.7) 0.16 0.02
-819C/C 1(4.2) 3(10.7) 0.36 0.62
-1082A/A 23(95.8) 25(89.3) 2.78 0.62
-1082A/G 1(4.2) 3(10.7) 0.36 0.62
-1082G/G 0(0) 0(0) - -
Heplotype n = 24 n = 28   
ATA 19(79.1) 13(46.4) 4.38 0.02
GCC 0(0) 3(10.7) - -
ACC 5(20.8) 12(42.8) 0.35 0.14
  1. NOTE: n is the number of patients or controllers. P values were caculated by Fisher Probability. P values less than 0.05 were considered statistically significant. SR: sustained response; NR: non-responders.